StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$9.76M. The highest annual figure on record is -$9.76M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.76M–
FY2024Dec 31, 2024-$16.34M–
FY2023Dec 31, 2023-$48.31M–
FY2022Dec 31, 2022-$28.50M–
FY2021Dec 31, 2021-$24.07M–
FY2020Dec 31, 2020-$21.99M–
FY2019Dec 31, 2019-$27.17M–
FY2018Dec 31, 2018-$25.06M–
FY2017Dec 31, 2017-$24.76M–
FY2016Dec 31, 2016-$16.03M–
FY2015Dec 31, 2015-$15.76M–

More BioLineRx figures

See a number that looks wrong?